Diagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines

Hemostasis disorders in cirrhosis / severe liver disease are complex, as they affect both pro- and anticoagulant factors, as well as pro- and antifibrinolytic components. Most of the tests that are used in clinical practice to assess coagulation do not take into account the compensatory capabilities of this system as a whole. This document provides guidance for the optimal application and interpretation of global screening tests in the assessment of hemostasis in cirrhosis/severe liver disease, analysis of risk factor of spontaneous and perioperative hemorrhagic complications in these patients, and possible ways to correct them. Thrombocytopenia is one of the most common hematological abnormalities in cirrhosis/ severe liver disease. The frequency of thrombocytopenia in such patients at the stage of liver cirrhosis is 70%, at the pre-cirrhotic stage – 6%. The latest scientific data on the use of thrombopoietin receptor agonists in chronic liver diseases are presented: which patients are the best candidates for a such of therapy. The rationality and limitations in prescribing blood components to patients with liver cirrhosis/severe liver diseases are described. Emphasis is placed on the fact that a number of hemorrhagic complications develop for other non-coagulopathic reasons: decompensated portal hypertension, traumatization of a varicose vein with trophic wall disorders, etc. Data are presented on the use of viscoelastic tests to optimize the management of patients with liver cirrhosis, which simultaneously assess the four main known components of the hemostasis system: the coagulation cascade, platelets, anticoagulant mechanisms and the fibrinolysis system. These tests allow optimization of transfusion of blood components in such patients and should be further studied. Research in this very complex area of hepatology is ongoing and must continue.

1. Blasi A. Coagulopathy in liver disease: Lack of an assessment tool. World J Gastroenterol. 2015;21(35):10062–10071. https://doi.org/10.3748/wjg.v21.i35.10062.

2. Ивашкин В.Т., Маевская М.В., Жаркова М.С., Жигалова С.Б., Киценко Е.А., Манукьян Г.В., Тихонов И.Н. Цирроз и фиброз печени: клинические рекомендации. М.; 2021. 99 с. Режим доступа: https://cr.minzdrav.gov.ru/schema/715_1. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Zhigalova S.B., Kitsenko E.A., Manukyan G.V., Tikhonov I.N. Cirrhosis and fibrosis of the liver: clinical guidelines. Moscow; 2021. 99 p. (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/715_1.

3. Moore A.H. Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options. Clin Liver Dis (Hoboken). 2019;14(5):183–186. https://doi.org/10.1002/cld.860.

4. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol. 2000;14(Suppl. D):60D–66D. https://doi.org/10.1155/2000/617428.

5. Reverter J.C. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost. 2006;4(4):717–720. https://doi.org/10.1111/j.1538-7836.2006.01887.x.

6. Tripodi A., Primignani M., Chantarangkul V., Clerici M., Dell’Era A., Fabris F. et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44(2):440–445. https://doi.org/10.1002/hep.21266.

7. Budnick I.M., Davis J.P.E., Sundararaghavan A., Konkol S.B., Lau C.E., Alsobrooks J.P. et al. Transfusion with Cryoprecipitate for Very Low Fibrinogen Levels Does Not Affect Bleeding or Survival in Critically Ill Cirrhosis Patients. Thromb Haemost. 2021;121(10):1317–1325. https://doi.org/10.1055/a-1355-3716.

8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. 2022;76(5):1151–1184. https://doi.org/10.1016/j.jhep.2021.09.003.

9. Меликян А.Л., Пустовая Е.И., Цветаева Н.В., Егорова Е.К. Идиопатическая тромбоцитопеническая пурпура (ИТП) у взрослых: клинические рекомендации. М.; 2021. 55 с. Режим доступа: https://cr.minzdrav.gov.ru/schema/150_2. Melikyan A.L., Pustovaya E.I., Tsvetaeva N.V., Egorova E.K. Idiopathic thrombocytopenic purpura (ITP) in adults: clinical guidelines. Moscow; 2021. 55 p. (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/150_2.

10. Kaufman R.M., Djulbegovic B., Gernsheimer T., Kleinman S., Tinmouth A.T., Capocelli K.E. et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–213. https://doi.org/10.7326/M14-1589.

11. Northup P.G., Garcia-Pagan J.C., Garcia-Tsao G., Intagliata N.M., Superina R.A., Roberts L.N. et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366–413. https://doi.org/10.1002/hep.31646.

12. Alvaro D., Caporaso N., Giannini E.G., Iacobellis A., Morelli M., Toniutto P., Violi F. Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest. 2021;51(6):e13508. https://doi.org/10.1111/eci.13508.

13. Park J.G., Park S.Y., Tak W.Y., Kweon Y.O., Jang S.Y., Lee Y.R. et al. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,843 ablations in 1,211 patients in a single centre: experience over 10 years. Clin Radiol. 2017;72(8):692.e9–692.e15. https://doi.org/10.1016/j.crad.2017.03.001.

14. Soh H., Chun J., Hong S.W., Park S., Lee Y.B., Lee H.J. et al. Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. Gut Liver. 2020;14(6):755–764. https://doi.org/10.5009/gnl19131.

15. Hughes M., Prescott C., Ekeledo J. Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. Technology appraisal guidance. NICE; 2020. Available at: https://www.nice.org.uk/guidance/ta626/.

16. Flisiak R., Antonov K., Drastich P., Jarcuska P., Maevskaya M., Makara M. et al. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures. J Clin Med. 2021;10(22):5419. https://doi.org/10.3390/jcm10225419.

17. Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis. 2016;48(5):455–467. https://doi.org/10.1016/j.dld.2016.02.008.

18. Kovalic A.J., Majeed C.N., Samji N.S., Thuluvath P.J., Satapathy S.K. Systematic review with meta-analysis: abnormalities in the international normalised ratio do not correlate with periprocedural bleeding events among patients with cirrhosis. Aliment Pharmacol Ther. 2020;52(8):1298–1310. https://doi.org/10.1111/apt.16078.

19. Giannini E.G., Giambruno E., Brunacci M., Plaz Torres M.C., Furnari M., Bodini G. et al. Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. Ann Hepatol. 2018;17(5):830–835. https://doi.org/10.5604/01.3001.0012.0775.

20. Заболотских И.Б., Синьков С.В., Лебединский К.М., Буланов А.Ю., Ройтман Е.В. Периоперационное ведение пациентов с нарушениями системы гемостаза. Анестезиология и реаниматология. 2018;(1):58–81. https://doi.org/10.17116/anaesthesiology201801-02158. Zabolotskikh I.B., Sinkov S.V., Lebedinskiy K.M., Bulanov A.Yu., Roitman E.V. Perioperative management of patients with hemostasis system disorders. Russian Journal of Anеsthesiology and Reanimatology. 2018;(1):58–81. (In Russ.) https://doi.org/10.17116/anaesthesiology201801-02158.

21. Галстян Г.М. Применение концентратов протромбинового комплекса по утвержденным и неутвержденным показаниям: новые перспективы старых препаратов. Гематология и трансфузиология. 2018;63(1):78–91. https://doi.org/10.25837/HAT.2018.30..1..008. Galstyan G.M. Label and off-label applications of prothrombin complex concentrates. New perspectives of old drugs. Gematologiya i Transfuziologiya. 2018;63(1):78–91. (In Russ.) https://doi.org/10.25837/HAT.2018.30..1..008.

22. Terrault N., Chen Y.C., Izumi N., Kayali Z., Mitrut P., Tak W.Y. et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology. 2018;155(3):705–718. https://doi.org/10.1053/j.gastro.2018.05.025.

23. Poordad F., Terrault N.A., Alkhouri N., Tian W., Allen L.F., Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. Int J Hepatol. 2020:5421632. https://doi.org/10.1155/2020/5421632.

24. Hidaka H., Kurosaki M., Tanaka H., Kudo M., Abiru S., Igura T. et al. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. Clin Gastroenterol Hepatol. 2019;17(6):1192–1200. https://doi.org/10.1016/j.cgh.2018.11.047.

25. Peck-Radosavljevic M., Simon K., Iacobellis A., Hassanein T., Kayali Z., Tran A. et al. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019;70(4):1336–1348. https://doi.org/10.1002/hep.30561.

26. Afdhal N.H., Giannini E.G., Tayyab G., Mohsin A., Lee J.W., Andriulli A. et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–724. https://doi.org/10.1056/NEJMoa1110709.

27. Анисимов А.Ю., Верткин А.Л., Девятов А.В., Дзидзава И.И., Жигалова С.Б., Затевахин И.И. и др. Клинические рекомендации по лечению кровотечений из варикозно расширенных вен пищевода и желудка. Воронеж; 2014. 45 с. Режим доступа: https://www.mrckb.ru/files/krovotecheniya_iz_varikoznorasshirennyx_ven_pishhevoda_i_zheludka.PDF. Anisimov A.Yu., Vertkin A.L., Devyatov A.V., Dzidzava I.I., Zhigalova S.B., Zatevakhin I.I. et al. Clinical recommendations for the treatment of bleeding from varicose veins of the esophagus and stomach. Voronezh; 2014. 45 p. (In Russ.) Available at: https://www.mrckb.ru/files/krovotecheniya_iz_varikoznorassirennyx_ven_pishhevoda_i_zheludka.PDF.

28. Tischendorf M., Fuchs A., Zeuzem S., Lange C.M. Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events. J Hepatol. 2019;70(4):800–801. https://doi.org/10.1016/j.jhep.2018.11.019.

29. Harwood M., Robinson C., Wood P. Too much of a good thing: two cases of disseminated intravascular coagulation-like coagulopathy in patients with decompensated cirrhosis after administration of Prothrombinex-VF. Intern Med J. 2019;49(5):679–680. https://doi.org/10.1111/imj.14272.

30. Franchini M., Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10(1):23–27. https://doi.org/10.2450/2011.0015-11.

31. Pereira A., Beltran J., Blasi A. Who advocates for cryoprecipitate? Transfusion. 2014;54(5):1442–1443. https://doi.org/10.1111/trf.12563.

32. Lisman T., Porte R.J. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878–885. https://doi.org/10.1182/blood-2010-02-261891.